IMV News and Press, IMV Inc. From 03/30/20

Launched development program for a DPX-based vaccine candidate against COVID-19 Reported updated Phase 2 data from DeCidE1 study in advanced ovarian cancer; These encouraging results support DPX-Survivac being amongst the first in vivo T cell therapy to demonstrate meaningful cli...

Plus Therapeutics. (NASDAQ: PSTV ) +63%   in-licenses novel oncology candidates. More news on: Plus Therapeutics, Inc., Bellerophon Therapeutics, Inc., Owens & Minor, Inc., Stocks on the move, , Read more ...

IMV (NASDAQ: IMV ) provides updates on the development of DPX-COVID-19, a vaccine candidate against coronavirus. More news on: IMV Inc., Healthcare stocks news, Stocks on the move, Read more ...

IMV Inc. (Nasdaq: IMV) (TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today provided updates on the development of DPX-COVID-19, a vaccine candidate against the novel coronavirus, and on the Company’s business and clinical o...

IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, announced today that it will hold a conference call and webcast on Wednesday, March 31, 2020 at 8:00 a.m. Eastern ...

Moderna ( MRNA -15.9% ) slumps on more than double normal volume on the heels of comments today from FDA Commissioner Stephen Hahn (during the Coronavirus Task Force briefing) that approval of a COVID-19 vaccine is at least a year away which is consistent with health authorities' expecta...

Biomerica (NASDAQ: BMRA ) +133%  on advancement of rapid coronavirus test. More news on: Biomerica, Inc., IMV Inc., Vaxart, Inc., Stocks on the move, , Read more ...

Capitalizing on its coronavirus vaccine -stoked rally, IMV (NASDAQ: IMV ) has inked an agreement with Piper Sandler for the at-the-market sale of up to $30M of its common stock. More news on: IMV Inc., Healthcare stocks news, Stocks on the move, , Read more ...

IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated March 18, 2020, with Piper Sandler & Co. ("Piper Sandler") as agent, pursuant to which the ...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company (the “Company” or “IMV”), today announced that it is advancing the clinical development of a DPX-based vaccine candidate against COVID-19. Vaccines against infectious disease have been a c...